Stankute, I.; Radzeviciene, L.; Monstaviciene, A.; Dobrovolskiene, R.; Danyte, E.; Verkauskiene, R.
Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients. Medicina 2022, 58, 218.
https://doi.org/10.3390/medicina58020218
AMA Style
Stankute I, Radzeviciene L, Monstaviciene A, Dobrovolskiene R, Danyte E, Verkauskiene R.
Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients. Medicina. 2022; 58(2):218.
https://doi.org/10.3390/medicina58020218
Chicago/Turabian Style
Stankute, Ingrida, Lina Radzeviciene, Ausra Monstaviciene, Rimante Dobrovolskiene, Evalda Danyte, and Rasa Verkauskiene.
2022. "Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients" Medicina 58, no. 2: 218.
https://doi.org/10.3390/medicina58020218
APA Style
Stankute, I., Radzeviciene, L., Monstaviciene, A., Dobrovolskiene, R., Danyte, E., & Verkauskiene, R.
(2022). Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients. Medicina, 58(2), 218.
https://doi.org/10.3390/medicina58020218